Establishing a state of transplantation tolerance that leads to indefinite graft survival without the need for lifelong immunosuppression has been achieved successfully in limited numbers of transplant recipients in the clinic. These successes led to studies aimed at identifying potential biomarkers that diagnose allograft tolerance and identify the patients most amenable to drug minimization, and implicated an enriched B cell signature of tolerance. The emergence of a specialized subset of regulatory B cell (B regs ), that possess immune-modulatory function in inflammation and autoimmune disease, raised the possibility that B regs play critical roles in the promotion of transplantation tolerance and that B regs are the underlying explanation for the B cell signature of tolerance. However, B cells are best known to play a key role in humoral immunity, and excessive production of donor specific antibodies has clear deleterious effects in transplantation. Thus, for tolerance to be persistent, alloantibody responses must also be curtailed, either through the suppression of T cell help or the induction of B cell-intrinsic dysfunction. Recent findings indicate a unique subset of follicular regulatory T cells (Tfr) that can suppress B cell function and induce epigenetic modifications that result in sustained defects in B cell differentiation and function. In this review, we summarize studies in animals and humans that suggest roles for B regs and dysfunctional B cells in transplantation tolerance, and discuss how these insights may provide a roadmap for new approaches to diagnose, and new therapies to induce allograft tolerance.
Introduction
High levels of donor-specific antibodies (DSA), that may either be preformed or develop de novo after transplantation, mediate antibody-mediated allograft rejection (AMR) that is now considered the leading cause of graft loss in the clinic [1, 2] . DSA can be produced by long-lived plasma cells without further need for antigen stimulation or T cell help, and they bind directly to graft endothelium to mediate acute AMR through the activation of complement and recruitment of FcgR 1 natural killer (NK) cells, macrophages and neutrophils [3, 4] . The classical histological features of acute AMR include platelet aggregation, thrombotic microangiopathy (TMA) and neutrophilic accumulation, resulting in early cellular necrosis and a relatively rapid decline in allograft function [5] . In chronic AMR a repetitive pattern of subacute thrombotic events and inflammatory changes results in cellular and repair, culminating as late transplant glomerulopathy and a gradual decline in renal function [6] . Thus, if immune tolerance is to maintain the allograft for the life of the recipient successfully, humoral responses have to be controlled. This control may be achieved by cell extrinsic mechanisms that are dependent upon the control of T follicular helper cells (Tfh), suppression by regulatory T follicular cells (Tfr) or by B cell intrinsic mechanisms (Fig. 1 ).
In 2010, two cross-sectional studies on renal transplant tolerance in humans unexpectedly identified an enriched B cell signature [7, 8] . The authors hypothesized that this enriched B cell signature of tolerance could, potentially, be used to guide the safe minimization or withdrawal of immunosuppressive therapy in certain transplant recipients. Furthermore, these observations, combined with the identification of B cells producing the T cell immunosuppressive cytokine, interleukin (IL)210, led to the hypothesis that this signature was indicative of a role for regulatory B cells (B regs ) in clinical tolerance. This hypothesis therefore expands the role for B cells from mediators of rejection to mediators of transplantation tolerance (Fig. 1 ).
Here we provide an overview on the rapidly evolving area of B cells in transplantation tolerance, discussing the findings of the B cell signature of tolerance, the potential role of IL-10-producing B cells as regulators of donorspecific T cell responses, and the mechanisms that curtail the differentiation of B cells into antibody-secreting cells during allograft tolerance.
B cell signature and tolerance in humans
When kidney transplant recipients discontinue their immunosuppressive medication, a very small number of patients continue to maintain good graft function for many years [7] [8] [9] . These recipients, labelled as 'operationally tolerant', have provided a unique opportunity to study the basis of clinical transplant tolerance. Indeed, the peripheral blood of these tolerant patients have been subject to many biomarker discovery investigations to identify a non-invasive gene signature of tolerance. The investigators reasoned that such a biomarker could be used in clinical trials to evaluate the effectiveness of potential tolerance induction therapies, and identify individuals that may be weaned successfully from immunosuppression and provide insights into the mechanisms of transplantation tolerance [10] .
Newell et al. [7] and Sagoo et al. [8] reported on a tolerance signature that comprised enrichment of genes involved in B cell activation and differentiation compared to stable recipients on immunosuppression. This signature from peripheral blood was confirmed with real-time polymerase chain reaction (PCR) gene expression analyses of urine sedimentary cells, and the three most predictive genes that clearly separated tolerant from immunosuppressed patients were immunoglobulin kappa variable 4-1 (IGKV4-1), immunoglobulin lambda-like polypeptide 1 (IGLL1) and immunoglobulin kappa chain variable region D-13 (IGKVD-13), while flow cytometry analysis confirmed the expansion of total B cells in tolerant compared to immunosuppressed recipients [7, 8] . In a separate study, Pallier et al. [11] reported a comparable increase in B cells in the blood of tolerant compared to immunosuppressed patients, especially those with an activated, memory and early memory phenotypes, as well as the up-regulation of co-stimulatory and inhibitory [B-cell scaffold protein with ankyrin repeats 1 (BANK1) and receptors for the Fc region of immunoglobulin G IIB (FcgRIIB)] molecules on those B cells.
One major caveat of those studies was that the B cell signature of tolerance arose from the comparison between tolerant and immunosuppressed recipients, thus the differences observed between these two groups could have been due to the effect of immunosuppression on the B cell differentiation rather than being a unique marker of tolerance that is more likely to be subtle. Indeed, no consistent difference in the gene profile or cell frequencies was detected when tolerant recipients were compared to healthy controls. A number of recent studies have addressed the impact of immune-suppression on the gene profile and cellular subsets in transplant recipients. Tebbe et al. [12] reported that calcineurin-inhibitors in renal transplant recipients reduced the numbers of B cells, especially the immature transitional CD19 [13] . They showed that patients on azathioprine or prednisone had lower percentages of transitional B cells compared to patients off each of these drugs, with steroids showing a clear dose-dependent effect. Calcineurin inhibitors had no effect on the tolerant gene signature or B cell frequencies. Finally, when the impact of immunosuppression was accounted for, a gene signature of five differentially expressed biological pathways was identified that differentiated between tolerant, immunosuppressed and healthy controls: nuclear factor kappa B (NF-jB), CD40, tumour necrosis factor (TNF), granulocyte-macrophage colonystimulating factor (GM-CSF) and glucocorticoid receptor regulatory network, with the CD40 pathway preferential to B cells. In addition, Bottomley et al. showed independently that the initial signatures of tolerance were influenced significantly by immunosuppressive agents [14] . Specifically, azathioprine decreased transitional and naive B cell numbers, whereas calcineurin inhibition was associated with increased numbers of plasmablast and class-switched memory B cells. Finally, Leibler et al. reported that in renal transplant patients, treatment with belatacept results in increased transitional and naive B cells, suggesting further that choice of immunosuppression influences B cell populations [15] . These data suggest collectively that the previously identified signature of transitional B cells in tolerant recipients is more likely to be a signature of immunosuppression and normalized B cell development in the absence of immunosuppression in tolerant recipients. Nevertheless, these data do not preclude an involvement of regulatory B cells in the development or maintenance of tolerance.
Regulatory B cells as mediators of tolerance
There is accumulating evidence that B cell-producing immunosuppressive cytokines can curtail T cells responses in autoimmunity, tumour immunity, infectious disease and transplantation tolerance [16] [17] [18] [19] [20] . These immunosuppressive B cells have been referred to as B regs [21, 22] , but it remains unclear whether B regs represent a developmentally specified and stable lineage comparable to forkhead box protein 3 (FoxP3 1 ) regulatory T cells or a differentiated subset of effector cells that secrete immunosuppressive cytokines preferentially, such as IL-10, IL-35 and transforming growth factor (TGF)-b. Despite considerable effort, studies that have performed gene arrays on B reg cells in mice [23] or humans [24] have not identified conclusively a lineage-specific marker equivalent to FoxP3. In line with the possibility that any B cell might differentiate potentially into a 'B reg ' cell in response to the right environmental stimuli, B cells that down-regulate immune [25] .
The lack of a definitive transcription factor or cell surface marker for B regs has made investigations into their biology challenging, and currently their quantification is dependent upon the expression of IL-10 either after invitro culture with phorbol myristate acetate (PMA) 1 ionomycin [25] or with anti-CD40, TLR agonists and inflammatory cytokines [22, 23] . Using both in-vitro and in-vivo approaches, B regs show various surface phenotypes consistent with being splenic marginal zone (MZ) [26] , MZ-precursor (MZ-P) or transitional 2 (T2) [16] , follicular [16, 27] CD1d hi CD5 1 B cells [28] , pro-B [29] and plasmablasts/plasma cells [30, 31] (Fig. 2 ).
In mice, the most widely investigated B reg population comprises the IL-10-producing B10 cells expressing CD19 1 CD5 1 CD1d hi ; these cells have been shown to modulate T cell function in models of experimental autoimmune encephalomyelitis (EAE) [32] , inflammatory bowel disease [33] , collagen-induced arthritis [34] and systemic lupus erythematosus (SLE) [35] . One way that B10 cells mediate suppression of T helper type 1 (Th1) and Th17 cell differentiation is through the suppression of dendritic cells [22, 36] . A different subset of regulatory B cells producing IL-35 has been reported to protect mouse models of EAE and increase susceptibility to the intracellular pathogen, Salmonella enterica serovar Typhimurium. IL-35 production by B cells was associated with reduced 
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-CD1d hi B cells produced IL-10 and the proinflammatory cytokine, IL-6 [23] . Matsumoto et al. also reported that plasmablasts express predominantly IL-10 during EAE induction, and was essential for the ability of dendritic cells to limit the generation of pathogenic T cells [30] . These observations, together with the identification of plasmablasts and plasma cells producing IL-10, IL-35, transfer RNA (TNR)-a, IL-17 and GM-CSF in various experimental conditions in mice, have led to the hypothesis of distinct subsets of terminally differentiated regulatory and effector B cells regulating and promoting T cell function, independently of antibody secretion [37] [38] [39] .
In experimental transplantation models, Ding et al. reported that B cells are required for Th2 cytokine expression induced by anti-TIM-1 for prolonged graft acceptance of allogeneic islets [19] . They showed that approximately 15% of B cells expressed TIM-1, and Tim-1 ligation induced IL-4 and IL-10 production by B cells that promoted a Th2 response. In addition, anti-Tim-1 treatment increased the percentage of Tim-1 1 IL-10 1 B cells with potential regulatory activity. Finally, they showed that TIM-1 identified the majority of IL-10-producing B cells across a wide spectrum of phenotypes, and concluded that TIM-1 may serve as an inducible and inclusive marker of B regs . A follow-up study by Yeung et al. reported that TIM-1 signalling was necessary for the maintenance and induction of B regs , and that B cells expressing a mutant form of TIM-1 that lacked the mucin domain was unable to produce IL-10 following ligation with anti-TIM-1. As anticipated, these mice with the mutant TIM-1 exhibited accelerated rejection that was prevented with the adoptive transfer of wild-type (WT) TIM-1 1 B cells [40] . In a model of islet transplantation, allograft tolerance induced by anti-CD45RB, which targeted a transmembrane protein phosphatase expressed on naive T cells and B cells, required B cells expressing CD40 and CD80/86 [41] . However, IL-10 was shown to have an unexpected counterregulatory function in an allogeneic heart transplant model where graft survival was extended with anti-CD45RB [42] . By using IL-10-deficient recipients, IL-10 neutralization and adoptive transfer of IL-10-deficient B cells into B celldeficient recipients, IL-10-deficiency enhanced tolerance and improved chronic allograft vasculopathy [42] . In a subsequent study, anti-TIM-1 was shown to synergize with anti-CD45RB to induce islet allograft tolerance that was dependent upon B cells, IL-10, regulatory T cells (T regs ) and TGF-b [43, 44] . These data suggest that the role of IL-10-producing B cells may be dependent upon the allograft type as well as the therapeutic agent used to induce allograft tolerance.
IL-10-producing B cells from the MZP B cell subset was reported to be necessary for anti-CD154 plus donor spleen cell-induced tolerance to cardiac allografts [45] . IL-10 was increased only in the MZP B cells that up-regulated IL-21R in tolerant recipients, and that were able to promote graft acceptance in B cell-specific IL-10-deficient recipients. These IL-10-producing MZP B cells controlled the differentiation and position of Th17, Tfh and Tfr cells in secondary lymphoid tissues [46] , thus providing contrasting mechanistic insights to previous studies on B regs , and underscoring the diversity in phenotype of IL-10-producing B cells that promote transplantation tolerance. Similarly, Durand et al. [47] 
CD24
hi CD38 hi B cells from healthy individuals, upon CD40 ligation, have the ability to inhibit the proliferation and differentiation of Th1 cells [48] . Their suppressive capacity was mediated in part by IL-10, and was reversed by anti-CD80 and CD86, consistent with a cognate-dependent suppression. In SLE patients, these CD19
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hi CD38 hi B cells were refractory to CD40 stimulation, produced less IL-10 and lack suppressive capacity, suggesting that alterations in B reg function 1 CD25 -T conv into T regs or to curb Th17 differentiation, but maintained their ability to inhibit Th1 development in vitro [49] .
B regs have also been described for renal transplant recipients. B regs enriched within the IgM memory and transitional subsets in healthy donors are deficient in chronic graft-versus-host disease (GVHD) [50] . Chesneau et al. [34] showed that B cells from tolerant patients have lower numbers of plasma cells compared to stable patients, and their activated B cells secreted more IL-10 compared to healthy subjects and stable immunosuppressed patients. These observations led to the conclusion that the combination of IL-10 production and defective B cell differentiation into plasma cells favoured the maintenance of transplantation tolerance. Indeed, Bigot et al. 
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hi transitional B cells (TrBs), CD24 hi CD27 1 memory B cells and naive B cells, the TrB subset had the highest IL-10/TNF-a ratio and suppressed Th1 cells more potently than memory B cells that expressed similar IL-10 but more TNF-a [54] . Collectively, it appears that IL-10 is essential but not a sufficient marker of B regs , and that reduced production of proinflammatory cytokines by these IL-10 B regs is additionally necessary to specify their ability to mediate T cell regulation and transplantation tolerance.
Anergy and regulation as mechanisms of B cell tolerance
There are ample clinical and experimental data showing the ability of alloantibodies to bind to graft endothelium and to mediate antibody-mediated rejection independently of T cells [55] [56] [57] . Therefore, if tolerance is to persist long term, alloantibody production has also to be controlled. Because alloantibody is predominantly T cell-dependent, it can be argued that restraining the alloreactive T cells, specifically the Tfh subset of cells that provide help to B cells, is sufficient to control B cell responses. However, under infection and inflammatory cytokines, B cells can differentiate into antibody-secreting plasmablasts and plasma cells with minimal requirement for T cell help, as has been described for autoimmune B cells, so additional B cell intrinsic mechanisms may be essential to reinforce selftolerance [58] .
Anergy, a condition in which cells persist in the periphery but are unresponsive to antigen, has been shown to be responsible for silencing self-reactive B cells that comprise more than half the B cell repertoire in mouse and man [59] [60] [61] . Multiple transgenic mouse models have been used in the early dissection of mechanisms that underlie anergy and several features that distinguish anergic B cells from naive B cells have been identified, including impaired signal transduction and tyrosine phosphorylation in response to B cell receptor (BCR) aggregation and elevated basal-intracellular-calcium concentration ([Ca 21 ] i ), but no further increase in [Ca 21 ] i upon BCR stimulation [62] [63] [64] [65] [66] . This defective BCR signalling results in reduced lifespan of the anergic B cells, altered migration and anatomical localization, and an inability to interact productively with helper T cells. Continuous inhibitory signalling pathways through tyrosine phosphatase Src homology region 2 1 domaincontaining phosphatase-1 (SHP-1) and the SH2-domaincontaining inositol phosphatase (SHIP-1) are required to maintain anergy, and inhibition of either of these pathways restored B cell activation, proliferation and generation of short-lived plasma cells [67] . Finally, anergic B cells have been reported as having an immature T3 [IgM mid , CD80 hi , CD95 hi , major histocompatibility complex (MHC) class II hi ] or a preplasma phenotype depending on the BCR specificity as well as ligand quality and quantity [60] .
The fate of endogenous (non-BCR-tg) self-reactive B cells that recognize the ubiquitously expressed transmembrane chicken ovalbumin (OVA) was reported by Taylor et al. [68] . They showed that tolerance was maintained by the deletion of BCR-expressing B cells with high affinity for OVA antigen and by anergy of the remaining B cells expressing low-affinity BCR to OVA. Despite functional unresponsiveness, the anergic B cells are indistinguishable phenotypically from functional naive OVA-specific B cells from WT mice based on the expression of CD24 [heat stable antigen (HSA)], CD38, CD40, CD44, CD80, CD86, CD95 (FAS), IgD, IgM and MHC-II.
Taylor et al. also reported that B cell responses to soluble antigen, glucose 6-phosphate isomerase, were inhibited as a result of an absence of T cell help [68] . T follicular helper (Tfh) CD4
1 T cells specialize in providing help to B cells [69] and, more recently, Tfr cells have been identified as a distinct subset of regulatory T cells derived from FoxP3 precursors that express high levels of C-X-C chemokine receptor type 5 (CXCR5) [which directs them to the germinal centre (GC)], programmed cell death protein 1 (PD-1), ICOS [70] and the canonical Tfh transcription factor B cell lymphoma 6 (Bcl6), albeit at a lower level than Tfh cells. Tfr cells have been shown to inhibit multiple states of B cell differentiation, but most importantly, to migrate into the GC to inhibit Tfh-mediated B cell activation [71] [72] [73] [74] [75] . While Linterman et al. reported that Tfr cells limited the outgrowth of non-antigen-specific B cells in the GC, thus specifying the GC reaction to antigen-specific B cells [72] , others have reported that Tfr limit antigen-specific responses [71, 73] . CD28 and ICOS are both essential for Tfr cell differentiation, cytotoxic T lymphocyte-associated protein 4 (CTLA-4) is essential for their maintenance and function, while PD-1 on Tfr down-regulates Tfh differentiation and function [74, 76, 77] . Sage et al. [78] showed subsequently that while key transcriptional signatures defining Tfh and its activation were maintained by Tfh from the Tfh-Tfr-B cell co-cultures, selective effector molecules and metabolic pathways were suppressed in ways that were distinct from T cell anergy or exhaustion. Similarly, Tfr-suppressed B cells underwent early activation and limited proliferation, but did not express the complete transcriptional programme of fully differentiated antibodysecreting cells. Specifically, the Myc, mechanistic target of rapamycin (mTOR) and metabolic pathways were suppressed in B cells during co-culture with Tfr and Tfh, and shown to be durable even in subsequent culture with Tfh cells and in the absence of T fr cells. This imprinting of Tfr suppression was shown to be due, at least in part, to epigenetic changes that could be overcome with IL-21 that acted on Tfr to diminish its suppressive capacity and on B cells to restore their differentiation into antibody-secreting cells. The authors speculated that Tfr suppressed Tfh and B cells by interrupting bidirectional co-stimulation of T cell-B cell immunological synapses [70, 75] . Consistent with defective Tfh promoting B cell tolerance, Chenouard et al. [79] recently compared Tfh cells in operationally tolerant with stable kidney transplant recipients to reveal a defect in their ability to stimulate IgG production by naive B cells, and reduced IL-21 production compared to Tfh cells from nontolerant recipients.
Anergic B cells have also been described in human peripheral blood. Duty Whether transplantation tolerance also induces a state of hyporesponsiveness on alloreactive B cells has not been well characterized. In models of central tolerance achieved through mixed bone marrow chimerism [83, 84] , B cell tolerance was shown to be dependent upon early anergy followed by the deletion. In a model of peripheral allograft tolerance induced by co-stimulation blockade to allogeneic heart grafts in BCR-transgenic recipients, Li et al. [85] reported that alloreactive B cells were deleted, whereas in a non-BCR-transgenic model of co-stimulation-induced tolerance, restoration of alloantibody responses required both the deletion of CD25 1 cells and the reconstitution of alloreactive B cells [86] . Whether the alloreactive B cells were deleted or dysfunctional in the non-BCR-transgenic model were not ascertained because of the inability to track the alloreactive B cells. Overall, compared to B cells with regulatory activity, the investigation into the basis for cell intrinsic B cell tolerance in transplantation is more limited. Nevertheless, evidence for anergy as a major mechanism controlling peripheral autoreactive B cells, either through the down-modulation of BCR signalling or suppression by Tfr cells, suggests that similar mechanisms may also be at play in allograft tolerance.
Conclusion
This review summarizes literature investigating B cells in transplantation tolerance, their limitations and future direction ( Table 2 ). Investigations into biomarkers of tolerance in the peripheral blood of tolerant renal transplant recipients suggested a key finding of the preservation of a B cell compartment with IL-10 production capacity and a deficiency in antibody-producing plasma cells. While these findings have been tempered by recent reports that immunosuppressive agents have profound effects on B cell subsets, B cells producing suppressive cytokines, including IL-10 and IL-35, to control T cell responses may nevertheless be essential contributors to transplantation tolerance. Indeed, there is considerable literature supporting this notion, although details of Breg provenance remain controversial. Furthermore, the control of T cell help may be over-ridden by inflammatory cues, so additional B cellintrinsic mechanisms may be necessary for robust tolerance. The mechanistic insights into B regs and B cell dysfunction may lead to new therapeutic approaches and guide ongoing efforts to identify reliable biomarkers for transplantation tolerance.
